KH617 for first recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new drug (KH617) for people with glioblastoma that has returned after initial treatment. It may offer a new option for those whose tumor type is not helped by standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have glioblastoma that has come back for the first time after standard treatment.
- Your tumor's MGMT gene is in the 'unmethylated' state (no switch).
- You are able to care for yourself (KPS score of 60 or higher).
- You have not had another type of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called CT-179, which targets a protein involved in brain tumor growth. It may help people with glioblastoma, a type of brain cancer, when standard treatments have not worked or as part of initial treatment.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.